RADBIO

RADBIO is a biotechnology company that develops novel biological drugs to treat complex chronic diseases associated with the TGF-beta signaling pathway. The company's lead therapeutic candidate, BRECEPT, is an Fc-fusion protein designed to function as a decoy receptor that neutralizes excessive TGF-beta levels. This molecule was developed based on the discovery of a soluble variant of the TGF-beta type II receptor and is being investigated for its antifibrotic and antitumor potential across various indications, including systemic sclerosis, liver fibrosis, wound healing, colorectal cancer, and breast cancer.

By targeting the TGF-beta pathway, RADBIO aims to address unmet medical needs in patients suffering from fibrotic conditions and solid tumors, where common cellular processes like epithelial-mesenchymal transition and extracellular matrix deposition are prevalent. The company has conducted preclinical studies demonstrating the efficacy of its approach in multiple disease models. Founded in 2018, RADBIO has actively presented its research findings at international biotechnology summits and has secured a strategic alliance with MBC BioLabs to support its corporate operations and development programs.